消除乙型肝炎的全球投资框架

StephenW

A global investment framework for the elimination of hepatitis B

    Jessica Howell
    Alisa Pedrana
    Sophia E. Schroeder
    Mark Thursz
    David Wilson
    Margaret Hellard
    Show all authors

Published:September 21, 2020DOI:https://doi.org/10.1016/j.jhep.2020.09.013
   
Highlights

    •
    The WHO has set global targets for elimination of hepatitis B by 2030.
    •
    To date, global investment in hepatitis B elimination activities has been limited.
    •
    We have developed a global investment framework for the elimination of hepatitis B to guide domestic and international investment.
    •
    This Health Policy paper outlines evidence to support the financial returns on investment in hepatitis B elimination, identifies national and international activities to achieve hepatitis B elimination targets and identifies potential funding sources.
    •
    The goal of this investment framework is to pave the way for countries to build the economic case for investment in national hepatitis B elimination programmes.

Background & Aims
More than 292 million people are living with hepatitis B worldwide and are at risk of death from cirrhosis and liver cancer. The World Health Organization (WHO) has set global targets for the elimination of viral hepatitis as a public health threat by 2030. However, current levels of global investment in viral hepatitis elimination programmes are insufficient to achieve these goals.
Methods
To catalyse political commitment and to encourage domestic and international financing, we used published modelling data and key stakeholder interviews to develop an investment framework to demonstrate the return on investment for viral hepatitis elimination.
Results
The framework utilises a public health approach to identify evidence-based national activities that reduce viral hepatitis-related morbidity and mortality, as well as international activities and critical enablers that allow countries to achieve maximum impact on health outcomes from their investments – in the context of the WHO's 2030 viral elimination targets.
Conclusion
Focusing on hepatitis B, this health policy paper employs the investment framework to estimate the substantial economic benefits of investing in the elimination of hepatitis B and demonstrates how such investments could be cost saving by 2030.
Lay summary
Hepatitis B infection is a major cause of death from liver disease and liver cancer globally. To reduce deaths from hepatitis B infection, we need more people to be tested and treated for hepatitis B. In this paper, we outline a framework of activities to reduce hepatitis B-related deaths and discuss ways in which governments could pay for them.

StephenW

消除乙型肝炎的全球投资框架

    杰西卡·豪威尔（Jessica Howell）
    艾丽莎·佩德拉纳（Alisa Pedrana）
    索菲亚·施罗德
    马克·瑟斯
    戴维·威尔逊
    玛格丽特·赫拉德
    显示所有作者

发布时间：2020年9月21日DOI：https：//doi.org/10.1016/j.jhep.2020.09.013
   
强调

    •
    世界卫生组织制定了到2030年消除乙型肝炎的全球目标。
    •
    迄今为止，全球在消除乙肝活动方面的投资是有限的。
    •
    我们已经制定了消除乙型肝炎的全球投资框架，以指导国内和国际投资。
    •
    本卫生政策文件概述了支持消除乙肝投资的财务回报的证据，确定了实现消除乙肝目标的国家和国际活动，并确定了潜在的资金来源。
    •
    该投资框架的目标是为各国奠定基础，为对国家乙型肝炎消除计划进行投资奠定经济基础。

背景与目标
全球有超过2.92亿人患有乙型肝炎，并有死于肝硬化和肝癌的危险。世界卫生组织（WHO）设定了到2030年消除作为公共卫生威胁的病毒性肝炎的全球目标。但是，目前全球对病毒性肝炎消除计划的投资水平不足以实现这些目标。
方法
为了激发政治承诺并鼓励国内外筹集资金，我们使用了已发布的建模数据和主要利益相关者访谈来开发投资框架，以证明消除病毒性肝炎的投资回报。
结果
该框架利用公共卫生方法来确定可减少病毒性肝炎相关发病率和死亡率的基于证据的国家活动，以及允许各国在其投资范围内使投资对其健康成果产生最大影响的国际活动和关键推动因素。 WHO的2030年病毒消除目标。
结论
该卫生政策文件以乙肝为重点，利用投资框架来估算投资于消灭乙肝的实质性经济利益，并说明到2030年如何节省投资。
放置摘要
乙型肝炎感染是全球范围内由肝病和肝癌致死的主要原因。为了减少由乙型肝炎感染引起的死亡，我们需要对乙型肝炎进行更多的检查和治疗。在本文中，我们概述了减少与乙型肝炎相关的死亡的活动框架，并讨论了政府可以为之支付的方式。